Little House Capital LLC Takes $589,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Little House Capital LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,402 shares of the company's stock, valued at approximately $589,000.

Several other institutional investors and hedge funds have also modified their holdings of IDXX. Norges Bank acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $412,258,000. GAMMA Investing LLC raised its holdings in IDEXX Laboratories by 59,810.7% in the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after purchasing an additional 916,898 shares during the period. Alyeska Investment Group L.P. acquired a new position in IDEXX Laboratories in the 4th quarter worth about $156,412,000. William Blair Investment Management LLC raised its holdings in IDEXX Laboratories by 701.6% in the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after purchasing an additional 369,471 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in IDEXX Laboratories by 221.3% in the 4th quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock worth $182,459,000 after purchasing an additional 303,966 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Stifel Nicolaus upped their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Morgan Stanley upped their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Leerink Partners upped their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Finally, Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $546.00.

IDEXX Laboratories Price Performance

IDXX stock opened at $531.32 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. The business has a 50 day simple moving average of $499.01 and a 200-day simple moving average of $450.75. The firm has a market capitalization of $42.73 billion, a PE ratio of 49.11, a price-to-earnings-growth ratio of 3.85 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $535.20.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.71 earnings per share. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.